World News: 09:14 GMT Thursday 6th December 2018. [Research and Markets via Globe Newswire via SPi World News]
Dublin, Dec. 06, 2018 (GLOBE NEWSWIRE) -- The drug pipelines has been added to offering.
This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Transthyretin Amyloidosis (ATTR) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Transthyretin Amyloidosis (ATTR) from 2016 to 2027 segmented by seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented as Diagnosed Prevalent Population of ATTR, Type-specific Diagnosed Prevalent Cases and Stage-Specific Diagnosed Prevalent Population of Familial Amyloid Polyneuropathy]scenario of Transthyretin Amyloidosis (ATTR) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), and Japan from 2016-2027. According to the report, total prevalent population of ATTR in the 7 major markets ranges from approximately 19,197 cases in 2016, growing during the study period [2016-2027].The report also estimates higher prevalence of ATTR in the Italy with 2,044 cases in 2016 followed by France. On the other hand, United Kingdom has the lowest prevalent population in 2016. The report estimates that the diagnosed prevalent population of ATTR will significantly increase during the study period [2016-2027].Hereditary transthyretin amyloidosis (hATTR) cases are segmented in to two segments which includes Familial Amyloid Polyneuropathy (FAP) and Familial Amyloid Cardiomyopathy (FAC) cases. In 2016, there were 5,201 cases of Familial Amyloid Polyneuropathy and of Familial Amyloid Cardiomyopathy in the 7MM.
Current treatment options for patients with TTR amyloidosis are limited, with only symptomatic treatment and transplantation. For patients diagnosed with TTR-FAP who have a mild or moderate disease and confirmed by genetic testing and biopsy, a liver transplant is the current standard of care. However, symptomatic treatment is used to provide immediate relief.Various mechanisms leading to TTR misfolding and fibril formation identified TTR tetramer stabilization as a rate-limiting event, leading to the development of several new pharmacologic therapies for patients with TTR-FAP. These stabilizing agents can be prescribed at an early stage in anticipation of liver transplantation, or, potentially, delaying the need for liver transplant.
Drugs use in the treatment of ATTR include-Tafamidis (disease-modifying agent that kinetically stabilizes) and Diflunisal (This drug is an NSAID that stabilizes TTR tetramers in vitro, preventing disaggregation, monomer release and amyloid fibril formation by misfolded TTR monomers).FDA has approved few drugs such as Vyndaqel (Pfizer Inc), Onpattro (Alnylam Pharmaceuticals), Tegsedi (Ionis Pharmaceuticals /Akcea Therapeutics) which are used for the treatment of Transthyretin Amyloidosis (ATTR).
Key players such as Corino Therapeutics are involved in developing therapies for Transthyretin Amyloidosis (ATTR).
Expected launch of emerging therapies such as CRX-1008: Corino Therapeutics therapies will significantly impact the Transthyretin Amyloidosis (ATTR) market during the study period (2016-2027).This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
1. Key Insights 2. Transthyretin Amyloidosis (ATTR): Overview at a Glance 2.1. Market Share (%) Distribution of Transthyretin Amyloidosis (ATTR): in 2016 2.2. Market Share (%) Distribution of Transthyretin Amyloidosis (ATTR): in 2027 3. Transthyretin-Related Amyloidosis: Disease Background and Overview 3.1. Introduction 3.2. Clinical aspects of ATTR 3.3. Types of Transthyretin Amyloidosis 3.4. Causes and Clinical Manifestations 3.5. Symptoms 3.6. Pathogenesis 3.7. Diagnosis 3.7.1. Tools for evaluating TTR-FAP progression 4. Epidemiology and Patient Population 4.1. Key Findings 4.2. Population and Forecast Parameters 4.3. 7MM Diagnosed Prevalent Population of ATTR 4.4. Type-specific Diagnosed Prevalent Population of hATTR in 7MM 5. Epidemiology by Country5.1. United States5.2. European Union Five5.3. United Kingdom5.4. Germany5.5. Italy5.6. Spain5.7. France5.8. Japan6. 7MM Diagnosed Prevalent and Surgery Cases of ATTR Related Carpal Tunnel Syndrome7. Current Treatment and Medical Practices7.1. Treatment Guidelines7.1.1. First European Consensus for the diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy8. Unmet Needs9. Marketed Drugs9.1. Key Cross Competition9.2. Vyndaqel: Pfizer Inc.9.2.1. Drug Description9.2.2. Mechanism of Action9.2.3. Regulatory Milestones9.2.4. Advantages & Disadvantages9.2.5. Safety and Efficacy18.104.22.168. Ongoing trial description, 2022.214.171.124. Product Profile9.3. Onpattro: Alnylam Pharmaceuticals9.3.1. Regulatory Milestones9.3.2. Other development activities9.3.3. Clinical Development9.3.4. Clinical Trials Information126.96.36.199. Safety and Efficacy188.8.131.52. Product Profile9.4. Tegsedi: Ionis Pharmaceuticals /Akcea Therapeutics9.4.1.Regulatory Milestones9.4.1. Other development activities9.4.2. Clinical Development9.4.3. Clinical Trials Information184.108.40.206. Safety and Efficacy220.127.116.11. Product Profile10. Emerging Therapies10.1. Key Cross Competition10.2. CRX-1008: Corino Therapeutics10.2.1. Regulatory Milestones10.2.2. Other development activities10.2.3. Clinical Development10.2.4. Clinical Trials Information10.2.4.1. Safety and Efficacy10.2.4.2. Product Profile11. Transthyretin Amyloidosis: Market Analysis11.1. Key Findings12. Transthyretin Amyloidosis: 7 Major Market Outlook12.1. Market size of Transthyretin Amyloidosis in 7MM13. Market Outlook by Country13.1. Transthyretin Amyloidosis: United States Market13.2. Transthyretin Amyloidosis: EU5 Market Outlook13.3. Germany Market Size13.4. France Market Size13.5. The United Kingdom Market Size13.6. Italy Market Size13.7. Spain Market Size13.8. Transthyretin Amyloidosis: Japan Market Analysis14. Market Drivers15. Market Barriers
For more information about this drug pipelines report visit
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs , Endocrine and Metabolic Disorders Drugs
Globe Newswire: 09:14 GMT Thursday 6th December 2018
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.